Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

A generalized plate method for estimating total aerobic microbial count.

¹ALZA Corporation, 1950 Charleston Road, Mountain View, CA 94043, USA. kho@alzus.jnj.com

PDA Journal of Pharmaceutical Science and Technology

|December 1, 2004

Summary

This study presents a mathematical model to enhance the U.S. Pharmacopeia (USP 61) microbial limit test for pharmaceutical bioburden. The flexible framework allows for adjusted methods and stricter criteria with smaller sample sizes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.

Journal of patient-reported outcomes·2026

Same author

Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data.

Canadian journal of gastroenterology & hepatology·2025

Same author

Photobiomodulation Treatment with a Home-Use Device for COVID-19: A Randomized Controlled Trial for Efficacy and Safety.

Photobiomodulation, photomedicine, and laser surgery·2024

Same author

Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2023

Same author

Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.

American journal of hematology·2022

Area of Science:

Pharmaceutical Microbiology
Analytical Chemistry
Regulatory Science

Background:

The U.S. Pharmacopeia (USP) Chapter 61 outlines a plate method for microbial limit tests, crucial for pharmaceutical quality control.
While comprehensive, the USP 61 method offers limited flexibility for diverse laboratory scenarios and sample types.

Purpose of the Study:

To develop a flexible mathematical and statistical framework for assessing total aerobic bioburden.
To enable adjustments to the USP 61 plate method for practical laboratory constraints.
To re-evaluate the interpretation of USP 61 results for greater accuracy.

Main Methods:

Mathematical modeling of the plate counting procedure.
Statistical analysis of assay parameters within a generalized framework.

Related Experiment Videos

Comparative analysis of the model with existing USP 61 guidance.

Main Results:

A statistical framework was developed to provide more definitive statements on total aerobic bioburden.
The plate method can be adapted using smaller test specimen quantities (less than 10 g or 10 mL) with adjusted acceptance criteria.
The current interpretation of USP 61 results was found to be overly aggressive.

Conclusions:

The developed framework enhances the adaptability and statistical rigor of microbial limit testing.
Adjustments to the USP 61 method are feasible, allowing for greater laboratory efficiency and flexibility.
A revised interpretation of results can lead to more accurate bioburden assessments in pharmaceutical products.